Thursday, October 11, 2012
Markus Hosang, General Partner at BioMedPartners, has a strong pharmaceutical and VC background. He was previously Venture Partner at MPM Capital. Prior to joining MPM in 2002, he was at Roche, where he served for nearly 20 years in several senior management positions in the Pharma R&D organization.
akampion: If you could give some advice to aspiring or very junior venture capital professionals, what would it be?
Markus Hosang: There are usually two approaches to becoming a venture capital professional. First, you can join as an Associate or Analyst pretty early on if you have a strong scientific background, combined with a business degree (MBA). The second route is gaining extensive management and executive expertise in big pharma or biotech companies and subsequently joining a VC firm as a Partner. In general, I believe that operational experience in pharma or biotech companies is very important if you want to succeed in the venture capital industry. Even Associates or Analysts should bring some years of industry experience, not just a strong scientific background. » Read more...
Monday, June 11, 2012
akampion: When we first met, you were with Paul Capital Partners and very actively scouting the European biotech scene for potential deals. Since then, you have founded TransformRx and now you are also a Director at Alma Bio Therapeutics – how did that come about?
Martin Austin: I left Paul Capital because in my view, the market for royalty funds was beginning to narrow and only companies with sufficient revenues could really fit into the investment model. At the same time, the market trend moved more towards development and R&D. So I was wondering how to address these developments, and so I eventually acquired the Swiss subsidiary of Paul Capital and founded TransformRx GmbH. » Read more...
Thursday, March 15, 2012
akampion: Can you tell us about the history of Venus Pharma?
SMS: Venus has its origin in the Indian generics industry and was founded in 1989 as Venus Remedies Ltd. However, the company meanwhile is very strong in innovative pharmaceutical products, in particular in fixed-dose combinations. Venus operates a large research center in India, which is accredited by the Indian government. Moreover, the company holds about 370 patents, has around 100 products and employs about 1,500 people in India alone. There are currently six offices worldwide – Venus Pharma GmbH was established in Germany in March 2006 and meanwhile has a staff of 15 full- and 30 part-time employees.
akampion: Why did the company decide to establish a German subsidiary? » Read more...
Friday, March 9, 2012
akampion: You are organizing a new conference called Innovations and Investments in Healthcare (IIHC). What is the idea behind this new event?
R.R.: I had been organizing an exclusive, invite-only German event for the past five years in Munich, but I felt it was time to open the format for new ideas and new people and also attract a broader, international audience. The past conferences have been very successful because we were not relying on the typical company presentations, but instead hosted interactive panels consisting of four experts and one senior partner of Roman Rittweger Advisors in Healthcare. No boring slides! The new event takes the concept even further and is, among others, inspired by the TED conferences.
» Read more...
Thursday, January 19, 2012
In 2006, long-time journalists Victoria English and William Ellington decided to quit their jobs and to establish their own publication, the biomedical trade journal MedNous (pronounced Med-Nows). A year later, in September 2007, the first issue appeared alongside with the website www.mednous.com.
akampion: Why did you establish MedNous?
Victoria English: Both of us thought Europe’s very innovative life science industry needed better communication. Back then, everyone was thinking in clusters and areas, and we felt by connecting the dots we could support the industry in its efforts to increase efficiency. Second, at that time the European Commission and the EMEA were very worried about the decreasing productivity of the biopharmaceutical industry, and Europe developed the Innovative Medicines Initiative, similar to the FDA’s Critical Path policy. This, too, called for better collaboration, and we wanted to capture this shift in official politics to encourage collaboration and translation of discoveries into products. Third, after working for many years in big corporations such as Reuters, DowJones, McGraw Hill and Informa, I thought it is time to start my own company. » Read more...